GSK (GSK) announced it has started shipping doses of its trivalent seasonal influenza vaccines to U.S. healthcare providers and pharmacies in preparation for the 2025-26 flu season. This immediately follows a licensing and lot-release approval from the FDA. Both Flulaval and Fluarix will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for people six months and older.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK Pharma call volume above normal and directionally bullish
- GSK’s Promising Phase 2b Study on Atopic Dermatitis Treatment
- GSK’s Belimumab Study: A Potential Game-Changer for Systemic Sclerosis Treatment?
- Drugmakers criticize Trump drug price negotiation plan, Bloomberg reports
- Pharma cos criticize Trump’s drug price negotiation plan, Bloomberg Law reports